Aatur Singhi, MD PhD
pancpathologist.bsky.social
Aatur Singhi, MD PhD
@pancpathologist.bsky.social
Pancreatobiliary & GI Pathologist. Early Detection #PancreaticCancer #Cholangiocarcinoma. And all things #NETs
Reposted by Aatur Singhi, MD PhD
New Journal for ImmunoTherapy of Cancer article: Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma bit.ly/4lcxHLC


@riyuesunnybao.bsky.social @pancpathologist.bsky.social
@zervanto.bsky.social @jasonlukemd.bsky.social

#JITC #cancer #MedSky
June 24, 2025 at 6:32 PM
Reposted by Aatur Singhi, MD PhD
🔥 Great discussion at the in person meeting of the GLOBAL GUIDELINES FOR CYSTIC TUMORS OF THE PANCREAS

expected to be released 🔜 stay tuned!

@letswinpc.org #HPBSky
May 5, 2025 at 3:32 PM
Reposted by Aatur Singhi, MD PhD
A huge majority of Americans (77%) oppose the cuts to medical research that the current administration has made.

(Source: Wash. Post/ABC/Ipsos poll)
April 28, 2025 at 8:48 PM
A little late, but what a wonderful time supporting #PancreaticCancer research at @pancan.bsky.social purplestride in Pittsburgh. @news.upmc.com @upmc.com @upmchillmancc.bsky.social
April 27, 2025 at 1:05 PM
Reposted by Aatur Singhi, MD PhD
If you or someone you love has been diagnosed with #pancreaticcancer, you’re not alone — we’re here to help. 💜 Our educational packets include essential resources to help you navigate next steps. Access these materials digitally 🖥️ or have them mailed to you 📬 by visiting pcan.at/skpmuj.
April 10, 2025 at 6:13 PM
Reposted by Aatur Singhi, MD PhD
This is catastrophic for pancreatic cancer patients
March 26, 2025 at 12:11 PM
Reposted by Aatur Singhi, MD PhD
In HER2-positive early #breastcancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival

Check out the full story 👇

www.curetoday.com/view/kadcyla...
Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer
In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.
www.curetoday.com
March 21, 2025 at 1:18 PM
Reposted by Aatur Singhi, MD PhD
Our incredible Team PanCAN runners are lacing up for the LA Marathon and Charity Half Marathon, and the United Airlines NYC Half Marathon today! 💜🏃‍♂️ They’ve spent months training and fundraising to make a difference for pancreatic cancer patients. Let’s show them some love in the comments!
March 16, 2025 at 12:00 PM
Reposted by Aatur Singhi, MD PhD
Serous Cystadenoma HOP with Vascular Map
December 23, 2024 at 10:39 PM
Reposted by Aatur Singhi, MD PhD
💥 A Stellar episode of our virtual meeting on pancreas topic.. this time IPMN 🍇 !!!

🚨 Integrating molecular testing to the evaluation of Pancreatic Cyst with the great @pancpathologist.bsky.social 🇺🇸 @upmc.bsky.social

Thank you, Aatur Singhi, for such a Christmas gift!!! 🎄

youtu.be/fF7HcPCqiwk
Integrating molecular testing to the evaluation of Pancreatic Cysts
YouTube video by Padova Pancreas Club
youtu.be
December 19, 2024 at 11:11 AM
Reposted by Aatur Singhi, MD PhD
Benign Pancreatic Tumors

Read more here: ctisus.com/learning/fea...
November 29, 2024 at 6:07 PM
Reposted by Aatur Singhi, MD PhD
More data on role of ATRX/DAXX loss for surgery in pancreas #NETs

👥116 PNETs in 🇯🇵

🧬11% DAXX & 7% ATRX loss 👉🏻intratumoral heterogeneity in 1/3

⬇️RFS with ATRX/DAXX loss

Should it be done routinely on all PNETs?

🔗 pubmed.ncbi.nlm.nih.gov/38909708/

#NETsSky #HPBSky #SurgSky #PancSky
November 27, 2024 at 10:08 PM
Reposted by Aatur Singhi, MD PhD
November 26, 2024 at 7:53 PM
Reposted by Aatur Singhi, MD PhD
Pancreatic Paraganglioma: CT Findings
ctisus.com/learning/fea...
November 26, 2024 at 7:07 PM
Reposted by Aatur Singhi, MD PhD
Is the other ALT (alternative lengthening of telomeres) ready for use in pNETs..? I think so, especially for prognostication after resection. Chromogenic ISH (CISH) easier to implement than FISH. Excellent stuff from Chris Heaphy, Aatur Singhi et al.
www.sciencedirect.com/science/arti...
Detection of Alternative Lengthening of Telomeres via Chromogenic in situ Hybridization (ALT-CISH) for the Prognostication of PanNETs and Other Neoplasms
Molecular studies have shown ALT to be an important prognostic biomarker of shorter relapse-free survival (RFS) for patients with pancreatic neuroendo…
www.sciencedirect.com
November 16, 2024 at 11:47 PM